Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $64.50 short put and a strike $59.50 long put offers a potential 6.61% return on risk over the next 12 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $64.50 by expiration. The full premium credit of $0.31 would be kept by the premium seller. The risk of $4.69 would be incurred if the stock dropped below the $59.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly Backs Lawsuit Against CMS Over its Alzheimer's Diagnostic Drug
Fri, 05 Sep 2014 14:24:09 GMT
Lilly's diabetes drug trumps Sanofi's in late-stage trials
Thu, 04 Sep 2014 13:46:40 GMT
Reuters – Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials. The drug, basal insulin peglispro, showed improved blood sugar levels, compared with Lantus in patients with type 1 diabetes as well as type 2. Lilly said it was on track to file a submission with the U.S. Lilly's drug is being studied as a once-daily treatment for both type 1 and type 2 diabetes.
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes
Thu, 04 Sep 2014 12:00:00 GMT
PR Newswire – INDIANAPOLIS, Sept. 4, 2014 /PRNewswire/ — Eli Lilly and Company's (LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus®) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. The Phase III trials needed for submission are now complete. The trials, in both type 1 and type 2 diabetes, showed consistent superiority of HbA1c for BIL against comparators. “These data are promising and give us further confidence in the clinical profile of BIL,” said Enrique Conterno, president, Lilly Diabetes. “Lilly is committed to meeting the diverse needs of people living with diabetes who need therapies that will help them meet their individual goals.
Can The Dutch Biotech Dezima Really Impact Heart Disease With Its HDL-Raising Drug?
Tue, 02 Sep 2014 12:21:00 GMT
EU regulators set Oct. 3 deadline for Eli Lilly, Novartis deal
Mon, 01 Sep 2014 10:50:42 GMT
Reuters – European Union competition regulators have until Oct. 3 to decide whether to approve U.S. drugmaker Eli Lilly and Co's $5.4 billion bid for Swiss peer Novartis's animal health business. The deal, which …
Related Posts
Also on Market Tamer…
Follow Us on Facebook